IO Biotech, Inc. (IOBT)
Largest Insider Buys in Sector
IOBT Stock Price History Chart
IOBT Stock Performance
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single …
Insider Activity of IO Biotech, Inc.
Over the last 12 months, insiders at IO Biotech, Inc. have bought $0 and sold $1.89M worth of IO Biotech, Inc. stock.
On average, over the past 5 years, insiders at IO Biotech, Inc. have bought $36.98M and sold $1.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $5,175 was made by Burkavage Brian (Chief Accounting Officer) on 2023‑11‑22.
List of Insider Buy and Sell Transactions, IO Biotech, Inc.
| 2024-07-26 | Sale | 10 percent owner | 23,478 0.0362% | $1.31 | $30,787 | -15.50% | ||
| 2024-07-25 | Sale | 10 percent owner | 51,522 0.0774% | $1.33 | $68,339 | -17.91% | ||
| 2024-05-10 | Sale | 10 percent owner | 658,809 0.8518% | $1.22 | $802,495 | -20.67% | ||
| 2024-02-09 | Sale | 10 percent owner | 658,809 0.8023% | $1.50 | $988,411 | -19.02% | ||
| 2023-11-22 | Chief Accounting Officer | 5,000 0.0076% | $1.03 | $5,175 | +40.40% | |||
| 2023-11-21 | Chief Accounting Officer | 5,000 0.0074% | $0.99 | $4,950 | +50.52% | |||
| 2023-08-09 | 10 percent owner | 2.47M 9.534% | $2.02 | $5M | -18.06% | |||
| 2023-08-09 | 10 percent owner | 3.16M 11.4408% | $1.90 | $6M | -18.06% | |||
| 2023-03-17 | Chief Financial Officer | 25,000 0.1017% | $2.32 | $58,018 | -8.59% | |||
| 2021-11-09 | 10 percent owner | 2.14M 51.9475% | $14.00 | $30M | -62.27% | |||
| 2021-11-09 | 10 percent owner | 325,000 7.8787% | $14.00 | $4.55M | -62.27% | |||
| 2021-11-09 | 10 percent owner | 650,000 15.7574% | $14.00 | $9.1M | -62.27% | |||
| 2021-11-09 | director | 650,000 15.7574% | $14.00 | $9.1M | -62.27% | |||
| 2021-11-09 | 10 percent owner | 325,000 7.8787% | $14.00 | $4.55M | -62.27% | |||
| 2021-11-09 | director | 75,000 1.8182% | $14.00 | $1.05M | -62.27% | |||
| 2021-11-09 | director | 325,000 7.8787% | $14.00 | $4.55M | -62.27% |
Insider Historical Profitability
| Novo Holdings A/S | 10 percent owner | 4354449 6.6096% | $0.77 | 2 | 4 | <0.0001% |
| Lundbeckfond Invest A/S | 10 percent owner | 6049452 9.1824% | $0.77 | 1 | 0 | <0.0001% |
| Vivo Capital IX, LLC | 10 percent owner | 3157894 4.7933% | $0.77 | 2 | 0 | <0.0001% |
| Nielsen Jack | director | 3015545 4.5773% | $0.77 | 1 | 0 | <0.0001% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2690545 4.084% | $0.77 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Vivo Capital | $10.68M | 9.37 | 6.17M | 0% | +$0 | 0.93 | |
| Novo Holdings A/S | $8.8M | 7.72 | 5.09M | -11.46% | -$1.14M | 0.62 | |
| Samsara Biocapital Llc | $6.3M | 5.53 | 3.64M | 0% | +$0 | 0.98 | |
| PFM Health Sciences | $4.05M | 3.55 | 2.34M | 0% | +$0 | 0.11 | |
| Morgan Stanley | $3.8M | 3.34 | 2.2M | -3.7% | -$146,095.05 | <0.0001 |